Indications
Therapeutic Asset Ratings
9,920 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Oricar-017
Lymphoproliferative Syndrome
OriCell Therapeutics Co., Ltd.
P1
CC
(43)
Oricar-017
Neoplasm
OriCell Therapeutics Co., Ltd.
P1
CC
(43)
Oricar-017
Plasma Cell Neoplasm
OriCell Therapeutics Co., Ltd.
P1
CC
(43)
Oricar-017
Monoclonal Paraproteinemia Disease
OriCell Therapeutics Co., Ltd.
P1
CC
(43)
Orm-6151
Cancer
Bristol-Myers Squibb
P1
CC
(43)
Osimertinib
Chemotherapy-Induced Toxicity
Blueprint Medicines Corporation
P1
CC
(43)
Osimertinib
Colorectal Neoplasm
AstraZeneca
P1
CC
(43)
Osimertinib
Epithelioid Hemangioendothelioma
Ikena Oncology
P1
CC
(43)
Osimertinib
Head And Neck Neoplasm
AstraZeneca
P1
CC
(43)
Osimertinib
Malignant Pleural Mesothelioma
Ikena Oncology
P1
CC
(43)
Osimertinib
NF2-Related Schwannomatosis
Ikena Oncology
P1
CC
(43)
Osimertinib
Respiratory System Disorder
Blueprint Medicines Corporation
P1
CC
(43)
Osivelotor
Kidney Failure
Pfizer
P1
CC
(43)
Ot-A201
Hematopoietic And Lymphoid System Neoplasm
Onward Therapeutics
P1
CC
(43)
Ots-412
Refractory Malignant Neoplasm
Bionoxx Inc.
P1
CC
(43)
Oxaliplatin
Cervical Cancer
Arcus Biosciences, Inc.
P1
CC
(43)
Oxaliplatin
Malignant Pleural Mesothelioma
Memorial Sloan Kettering Cancer Center
P1
CC
(43)
Oxaliplatin
Gastric Carcinoma
Alliance for Clinical Trials in Oncology
P1
CC
(43)
Oxaliplatin
Glioma
Pfizer
P1
CC
(43)
Oxaliplatin
Uterine Cancer
City of Hope Medical Center
P1
CC
(43)
Oxaliplatin
Appendix Adenocarcinoma
City of Hope Medical Center
P1
CC
(43)
Oxaliplatin
Uterine Corpus Cancer
City of Hope Medical Center
P1
CC
(43)
Oxaliplatin
Thyroid Cancer
Pfizer
P1
CC
(43)
Oxodotreotide
Head And Neck Cancer
National Cancer Institute (NCI)
P1
CC
(43)
Oxodotreotide
Kidney Cancer
National Cancer Institute (NCI)
P1
CC
(43)
Showing 3676 to 3700 of 9,920 assets
Previous
Page 148 of 397
Next
